Introduction {#s1}
============

Cancer is a complex ecosystem composed of cells with heterogeneous functional states, leading to both therapeutic resistance, and frequent cancer recurrence or metastasis, which poses a major obstacle to cancer diagnosis and treatment ([@B1]--[@B3]). Some tumor cells have high proliferative or apoptotic capacity, some have invasion and metastasis activities, some show stem-like properties, and some exhibit a quiescent state ([@B4], [@B5]). These functionally heterogeneous cancer cells act cooperatively or competitively during tumor progression or metastasis, leading to distinct tumor phenotypes ([@B6]--[@B8]). Therefore, it is essential to systematically and comprehensively identify the functional states of cancer cells.

Single-cell mRNA-sequencing (scRNA-seq) provides a powerful tool for characterizing the omic-scale features of heterogeneous cell populations ([@B9], [@B10]). ScRNA-seq technologies permit the dissection of primary tumor cells, metastatic tumor cells, cancer stem cells (CSC), circulating tumor cells (CTC), and disseminated tumor cells in a comprehensive and unbiased manner, with no need of any prior knowledge of the cell population. ScRNA-seq has become a reference tool for analyzing the composition of cancer tissues and for establishing the characteristics of the cellular microenvironment ([@B11]). Thus, understanding single cancer cells will advance our understanding of not only therapeutic resistance but all facets of cell biology. Furthermore, the application of scRNA-seq in the clinic has the potential to change our approach to cancer management fundamentally ([@B12]).

Zinc finger protein 671 (*ZNF671*) is a member of the KRAB-ZF (KRAB-ZFP) family of mammalian transcriptional repressors ([@B13]--[@B15]). KRAB-ZFPs can regulate tumor cell differentiation, proliferation, apoptosis, invasion, metastasis, and transformation ([@B16]--[@B21]). Previous studies showed that *ZNF671* could act as a tumor suppressor in several solid tumors ([@B22]--[@B26]). Our studies identified that *ZNF671* played a tumor suppressor role in breast invasive carcinoma (BRCA), cervical squamous cell carcinoma, and endocervical adenocarcinoma (CESC), head and neck squamous cell carcinoma (HNSC), kidney renal papillary cell carcinoma (KIRP), lung adenocarcinoma (LUAD), pancreatic adenocarcinoma (PAAD), and uterine corpus endometrial carcinoma (UCEC) ([@B26], [@B27]). However, the roles of *ZNF671* in the functional heterogeneity of cancer single cells remain unclear.

In this study, we analyzed the expression of *ZNF671* in cancer scRNA-seq datasets systematically. We explored the functional role of *ZNF671* in solid tumors and analyzed its expression and functional correlation in tumors. We further described the distribution of cancer single cells and explored their functional relevance in different tumor cell subgroups. Our results provide important insights into tumor heterogeneity and enhance knowledge of the tumor suppressor role of *ZNF671* in solid tumors.

Materials and Methods {#s2}
=====================

Data Collection
---------------

Data were collected based on the following keywords: ("single cells" OR "single cell" OR "single-cell" OR "single-cells") AND ("transcriptome" OR "transcriptomics" OR "scRNA-seq" OR "scRNA seq" OR "RNA-sequencing" OR "RNA-seq" OR"RNA sequencing") AND ("carcinoma" OR "tumor" OR "tumor" OR "cancer" OR "neoplasm" OR "neoplastic"). According to the method used by Yuan et al. ([@B28]), three human data sets from Array Express, Sequence Read Archive (SRA), and Gene Expression Omnibus (GEO) datasets were collected and all single-cell data in these datasets were analyzed via expression quantification, quality control, and characterization of functional states.

Data Processing
---------------

Transcript expression quantification was performed using Salmon (version 0.9.1) with the optional parameter *k* (*k* = 31 for long reads and *k* = 15 for short reads). The GENCODE (Release 28, GRCh38) reference transcriptome was used to detect gcBias, seqBias, and other default parameters in the quasi-mapping-based mode. For scRNA-seq datasets with only an expression matrix, we directly converted the expression values to transcripts per million (TPM)/counts per million (CPM) values using a custom script. Expression values were log2 transformed with an offset of 1.

Characterizing Functional States of Cancer Single Cells
-------------------------------------------------------

After reviewing cancer single-cell sequencing studies, 14 crucial functional states of cancer cells were selected, including angiogenesis, apoptosis, cell cycle, differentiation, DNA damage, DNA repair, epithelial--mesenchyme transition (EMT), hypoxia, inflammation, invasion, metastasis, proliferation, quiescence, and stemness using Gene Ontology, MSigDB, Cyclebase, HCMDB, and StemMapper ([@B29]--[@B33]). According to the method used by Yuan et al. ([@B28]), the activities of the 14 functional states across cancer single cells in the datasets were assessed using the Gene Set Variation Analysis (GSVA) package downloaded from <http://www.bioconductor.org> ([@B34]).

Dimensionality Reduction Using t-distributed Stochastic Neighbor Embedding (t-SNE) Analysis
-------------------------------------------------------------------------------------------

According to the method used by Li et al. ([@B35]), donor files were imported into R, and expression matrices containing measured intensities at the single-cell level were extracted from the flowCore package. A subset of cells was selected for each donor at random and merged into a single expression matrix before t-SNE analysis. The beads, viability, center, offset, residual, event length, intercalator, and time channels were removed from the expression matrix. The *ZNF671* protein marker was the only factor included in the t-SNE analysis, and *ZNF671* intensities were transformed using the inverse hyperbolic sine (arcsinh) function.

T-SNE calculations were performed with 1,000 iterations, a perplexity parameter of 30, and a trade-off θ of 0.5, which was used to visualize similarities and the proximity of cells in a two-dimensional plot. T-SNE maps were generated by plotting each event of the t-SNE dimensions in a dot-plot. *ZNF671* intensities were overlaid on the dot-plot to show the expression in different cell islands and to facilitate the assignment of cell subsets to these islands. The t-SNE dimensions were characterized by t-SNE1 and t-SNE2 in the given graphs. The software is available at <https://github.com/KlugerLab/FIt-SNE>.

*ZNF671* Expression and Functional State Correlation Analysis
-------------------------------------------------------------

The expression level statistics of *ZNF671* in each cell were converted to normalized ranks and Next, the Kolmogorov--Smirnov liker random walk statistic, similar to the GSEA method, was used to summarize the *ZNF671* expression-level rank statistics of a given signature gene set into a final enrichment score, which was used to characterize the signature activity. The enrichments of 14 signatures across cells in the scRNA-seq data were calculated, and only cells with detectable expression of *ZNF671* were used. Correlations between *ZNF671* expression and functional state activities were assessed using correlation analysis with false discovery rate (FDR) corrections for multiple comparisons (FDR \< 0.05 and *P* \< 0.05).

Cell Culture
------------

Human GBM cell lines (U87 and U251), the A375 melanoma cell line, and triple-negative breast cancer cell lines (MDA-MB-231 and BT-549) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were maintained at 37°, 5% CO~2~ in 10% DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum.

Western Blot Analysis
---------------------

After cells were transfected with the pEnter-*ZNF67*1 or pEnter-*vector* plasmids (Vigene Biosciences, Shandong, China) for 48 h, RIPA lysis buffer (Beyotime, Shanghai, China) was used to isolate proteins. Proteins were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (SDS-PAGE, Beyotime), transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA), and incubated with primary anti-ZNF671 (1:500; Proteintech, Chicago, IL, USA), E-cadherin (1:500, BD Biosciences), Vimtenin (1:500, BD Biosciences), and anti-GAPDH (1:1,000, Proteintech, Chicago, IL, USA).

Migration and Invasion Assays
-----------------------------

Transwell plates (8-μm pores) (Costar/Corning, Lowell, MA) were used for Transwell migration or invasion assays. 5 × 10^4^ (migration assay) or 1 × 10^5^ (invasion assay) cells resuspended in serum-free medium were placed in the upper chamber of each insert, either uncoated or coated with Matrigel (BD Biosciences). The lower chamber contained culture medium with 10% FBS to act as a chemoattractant. The cells were incubated for 12 or 24 h and were then fixed and stained. Cells on the undersides of the filters were observed and counted under 200× magnification.

Statistical Analysis
--------------------

Statistical analysis was performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). Differences between two groups were analyzed using the two-tailed unpaired Student\'s *t*-test; *P* \< 0.05 was considered statistically significant.

Results {#s3}
=======

scRNA-seq Dataset Features
--------------------------

As shown in [Table 1](#T1){ref-type="table"}, a total of eight cancer-related *ZNF671* scRNA-seq datasets were included in the study. They contained 14 functional states of 13941 cancer single cells from glioblastoma (GBM; *n* = 623), glioma (brain; *n* = 2259), glioma (PDX; *n* = 167), astrocytoma (AST; *n* = 5097), oligodendroglioma (ODG; *n* = 4043), lung adenocarcinoma (LUAD; *n* = 126), melanoma (MEL; *n* = 1257), and breast cancer (BRCA; *n* = 369).

###### 

Features of the scRNA-seq datasets searched with *ZNF671*.

  **ExpID**   **Name**                                   **Cancer**            **No. Cells**
  ----------- ------------------------------------------ --------------------- ---------------
  0058        Patel AP. Science. 2014 (Brain)            Glioblastoma          623
  0059        Filbin MG.Science. 2018 (Brain)            Glioma                2259
  0060        Filbin MG.Science. 2018 (PDX)              Glioma                167
  0056        Venteicher AS. Science. 2017 (Brain)       Astrocytoma           5097
  0062        Tirosh I. Nature. 2016 (Brain)             Oligodendroglioma     4043
  0066        Kim KT. Genome Biol. 2015 (PDX)            Lung adenocarcinoma   126
  0071        Tirosh I. Science. 2016 (Skin)             Melanoma              1257
  0052        Braune EB. Stem Cell Reports. 2016 (PDX)   Breast cancer         369

*ZNF671* Functional States in the scRNA-seq Datasets
----------------------------------------------------

Expression analysis showed that *ZNF671* was obviously downregulated in GBM, glioma, AST, ODG, LUAD, MEL, and BRCA ([Figure 1](#F1){ref-type="fig"}), which indicated that *ZNF671* might play an important role in tumor progression. To further explore the functional role of *ZNF671* in different cancers, 14 crucial functional states of cancer cells, including angiogenesis, apoptosis, cell cycle, differentiation, DNA damage, DNA repair, EMT, hypoxia, inflammation, invasion, metastasis, proliferation, quiescence, and stemness were summarized and analyzed. As shown in [Figure 2](#F2){ref-type="fig"}, the expression of *ZNF671* and the activity of each functional state across single-cell datasets in different cancers were explored using an interactive bubble chart. The upper bar plot shows a summary of the association between the functional state and the number of single-cell datasets. We found that the expression of *ZNF671* had a significant negative regulation for angiogenesis, apoptosis, EMT, hypoxia, invasion, and quiescence, which was consistent with our previous research ([@B26], [@B27]). These results indicate that *ZNF671* might play a suppressor role in tumor development.

![*ZNF671* is downregulated in primary solid tumors. Box diagram indicates the expression distribution of *ZNF671* in cells in the scRNA-seq datasets. Glioblastoma (GBM), Glioma (Brain), Glioma (PDX), Astrocytoma (AST), Oligodendroglioma (ODG), Lung adenocarcinoma (LUAD), Melanoma (MEL), and Breast cancer (BRCA). \*\**p* ≤ 0.01 compared with the control using Student\'s *t*-test.](fonc-09-01214-g0001){#F1}

![Relevance of *ZNF671* across 14 functional states in distinct cancers. The upper bar chart shows the number of datasets in which *ZNF671* is significantly related to the corresponding state. In the bubble chart in the second section, a results table is used to display the basic information of all single-cell datasets in the selected cancer type and the corresponding correlations with the 14 functional states. Glioblastoma (GBM), Glioma (Brain), Glioma (PDX), Astrocytoma (AST), Oligodendroglioma (ODG), Lung adenocarcinoma (LUAD), Melanoma (MEL), and Breast cancer (BRCA).](fonc-09-01214-g0002){#F2}

The Different Roles of *ZNF671* in Cancers
------------------------------------------

We next explored the functional roles of *ZNF671* in cancers, and analyzed the correlation between *ZNF671* expression and functional state. We found that *ZNF671* was positively associated with DNA damage (*R* = 0.18; \*\*\**P* \< 0.001), apoptosis (*R* = 0.13; \**P* \< 0.05), DNA repair (*R* = 0.10; \**P* \< 0.05) in GBM; with stemness (*R* = 0.11; \**P* \< 0.05) and inflammation (*R* = 0.06; \**P* \< 0.05) in AST; with proliferation (*R* = 0.29; \*\**P* \< 0.01), quiescence (*R* = 0.23; \**P* \< 0.05), and differentiation (*R* = 0.21; \**P* \< 0.05) in MEL; with inflammation (*R* = 0.17; \*\*\**P* \< 0.001), metastasis (*R* = 0.16; \*\*\**P* \< 0.001), stemness (*R* = 0.15; \*\**P* \< 0.01), hypoxia (*R* = 0.13; \*\**P* \< 0.01), EMT (*R* = 0.13; \**P* \< 0.05), and differentiation (*R* = 0.08; \**P* \< 0.05) in ODG; with EMT (*R* = 0.12; \**P* \< 0.05) and hypoxia (*R* = 0.12; \**P* \< 0.05) in glioma (brain); and with stemness (*R* = 0.18; \**P* \< 0.05), and hypoxia (*R* = 0.18; \**P* \< 0.05) in BRCA ([Figures 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}).

![Functional relevance of *ZNF671* in primary solid tumors. *ZNF671* plays different functional states in different single-cell datasets. Glioblastoma (GBM), Glioma (Brain), Glioma (PDX), Astrocytoma (AST), Oligodendroglioma (ODG), Lung adenocarcinoma (LUAD), Melanoma (MEL), and Breast cancer (BRCA). \*\*\**p* ≤ 0.001; \*\**p* ≤ 0.01; \**p* ≤ 0.05 compared with the control using Student\'s *t*-test.](fonc-09-01214-g0003){#F3}

![Correlations between *ZNF671* mRNA expression and functional states in primary solid tumors. The detailed functional relevance in each specific cell group of a specific scRNA-seq dataset is shown. Glioblastoma (GBM), Glioma (Brain), Glioma (PDX), Astrocytoma (AST), Oligodendroglioma (ODG), Lung adenocarcinoma (LUAD), Melanoma (MEL), and Breast cancer (BRCA).](fonc-09-01214-g0004){#F4}

However, *ZNF671* was negatively associated with DNA damage in ODG (*R* = −0.11; \*\**P* \< 0.01); with hypoxia (*R* = −0.55; \**P* \< 0.05), EMT (*R* = −0.50; \**P* \< 0.05), apoptosis (*R* = −0.49; \**P* \< 0.05), angiogenesis (*R* = −0.48; \**P* \< 0.05), and quiescence (*R* = −0.43; \**P* \< 0.05) in glioma (PDX), and with inflammation (*R* = −0.20; \**P* \< 0.05) and differentiation (*R* = −0.18; \**P* \< 0.05) in BRCA ([Figures 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}). These results indicated that *ZNF671* plays a different functional role in cancers and that the functional difference could be associated with the functional populations of cancer cells.

The Different Roles of *ZNF671* in Different Cell Groups
--------------------------------------------------------

To determine the functionally heterogeneous roles of *ZNF671* in cancer cells, we inferred that single cells exhibited widespread heterogeneity in terms of their functional states in cancer. We applied t-SNE to reduce the non-linear dimensionality of the cancer cell data and placed different cell clusters on a t-SNE map ([Figure 5](#F5){ref-type="fig"}), which indicated that the cell groups might be associated with the functional heterogeneity of cancer.

![The distribution of heterogeneous cell groups. Tridimensional t-SNE representation of cell clusters in primary tumors after classic multidimensional scaling and dimensionality reduction. Every point represents a single cell, and the color of the point represents the expression level of the gene (gene list) in the cell. Glioblastoma (GBM), Glioma (Brain), Glioma (PDX), Astrocytoma (AST), Oligodendroglioma (ODG), Lung adenocarcinoma (LUAD), Melanoma (MEL), and Breast cancer (BRCA).](fonc-09-01214-g0005){#F5}

To reveal the roles of *ZNF671* in different cell groups, we further the explored functional roles and correlations of *ZNF671* in different cancer subgroups. As shown in [Figure 6](#F6){ref-type="fig"}, *ZNF671* expression was positively associated with DNA repair, DNA damage, and apoptosis but negatively associated with angiogenesis, differentiation, and proliferation in MGH30 cell groups of GBM, while *ZNF671* expression was positively associated with proliferation in MGH31 cell groups of GBM. In glioma (brain), *ZNF671* expression was negatively correlated with angiogenesis in MUV1, with DNA repair, DNA damage, and cell cycle in MUV5, with DNA repair in BCH836, and with apoptosis in BCH869. *ZNF671* expression was positively correlated with hypoxia in MUV10, BCH836, and BCH869 in glioma (brain). In glioma (PDX), *ZNF671* expression in BCH869 correlated negatively not only with hypoxia but also with EMT, apoptosis, angiogenesis, and quiescence. In AST, *ZNF671* expression was positively correlated with stemness in MGH45 and MGH56, with invasion in MGH61, and with inflammation in MGH64, and it was negatively correlated with cell cycle and invasion in MGH45, with angiogenesis in MGH57, and with invasion in MGH64. In ODG, *ZNF671* expression was positively correlated with metastasis, hypoxia, inflammation, and apoptosis in MGH36 and with inflammation in MGH60 but negatively correlated with apoptosis in MGH54 and with quiescence in MGH93. Similarly, in MEL, *ZNF671* expression was positively correlated with stemness in tumor78, with proliferation and stemness in tumor79, with proliferation and differentiation in tumor88, and with inflammation in tumor89. However, *ZNF671* expression was negatively correlated with DNA repair in tumor78, DNA damage and angiogenesis in tumor80, and cell cycle in tumor89. In LUAD, *ZNF671* expression was positively correlated with DNA repair in MBT15 but negatively correlated with metastasis and invasion in PT45. In BRCA, *ZNF671* expression was only positively correlated with DNA damage in CSL KO xenograft tumor ([Figure 6](#F6){ref-type="fig"}, all \**P* \< 0.05; \*\**P* \< 0.01).

![Detailed functional relevance of *ZNF671* in different specific cell groups. The detailed functional relevance of *ZNF671* in each specific cell group of a specific dataset. Glioblastoma (GBM), Glioma (Brain), Glioma (PDX), Astrocytoma (AST), Oligodendroglioma (ODG), Lung adenocarcinoma (LUAD), Melanoma (MEL), and Breast cancer (BRCA). \*\**p* ≤ 0.01; \**p* ≤ 0.05 compared with the control using Student\'s *t*-test.](fonc-09-01214-g0006){#F6}

*ZNF671* Inhibits Cell EMT, Migration, and Invasion *in vitro*
--------------------------------------------------------------

To determine the functional roles of ZNF671 in cancer cells, we performed Western blot assay and migration and invasion assays using U87, U251, A375, MDA-MB-231, and BT-549 cell lines transfected with *ZNF671* or vector plasmids. As shown in [Figure 7A](#F7){ref-type="fig"}, Western blot analysis validated that ZNF671 protein was obviously upregulated after transfection of *ZNF671* plasmid. Furthermore, the overexpression of ZNF671 was associated with increased expression of the epithelial marker E-cadherin and decreased expression of the mesenchymal marker Vimentin. Transwell assays showed that overexpression of ZNF671 inhibited cancer cell migration and invasion *in vitro* ([Figures 7B--D](#F7){ref-type="fig"}). These findings indicate that ZNF671 inhibits the EMT, migration, and invasion of U87, U251, A375, MDA-MB-231, and BT-549 cells *in vitro*.

![Effects of ZNF671 overexpression on EMT, migration, and invasion *in vitro*. **(A)** Representative western blot analysis of ZNF671 overexpression in U87, U251, A375, MDA-MB-231, and BT-549 cell lines. **(B,C)** Representative images of the effects of ZNF671 overexpression on the migratory and invasive abilities of cells as determined by Transwell migration **(B)** and invasion **(C)** assays. **(D)** Quantification of the effects of ZNF671 overexpression on migratory and invasive abilities. All of the experiments were performed at least three times. Data presented are the mean ± SD; \*\**P* \< 0.01. All of the experiments were performed at least three test.](fonc-09-01214-g0007){#F7}

Discussion {#s4}
==========

*ZNF671*, which contains C2H2-type zinc fingers (ZFs) and a Krüppel-associated box (KRAB) domain, is a member of the KRAB-ZF (KRAB-ZFP) transcriptional family. KRAB-ZFPs are involved in regulating angiogenesis ([@B36]), apoptosis ([@B37]--[@B39]), the cell cycle ([@B40], [@B41]), inflammation ([@B42]), invasion and metastasis ([@B43], [@B44]), and stemness ([@B45]). Our previous studies demonstrated that *ZNF671* is a tumor suppressor that is epigenetically silenced by DNA methylation in nasopharyngeal carcinoma, BRCA, CESC, HNSC, KIRP, LUAD, PAAD, and UCEC ([@B26], [@B27]). However, there is limited information regarding the role of *ZNF671* in cancer progression and development, and there have been no systematic studies of the role of *ZNF671* in cancer\'s heterogeneous functional states.

In this study, we found a total of eight solid tumor-related *ZNF671* scRNA-seq datasets, including GBM, glioma, AST, ODG, LUAD, MEL, and BRCA. ScRNA-seq functional state analysis showed that *ZNF671* played a tumor suppressor role and/or an oncogenic role in angiogenesis, apoptosis, cell cycle, differentiation, DNA damage, DNA repair, EMT, hypoxia, inflammation, invasion, metastasis, proliferation, quiescence, and stemness. The different functional states in tumors may be associated with the inherent heterogeneity of the tumor. However, the synthetic analysis of eight solid tumors showed that *ZNF671* was negatively associated with angiogenesis, apoptosis, EMT, hypoxia, invasion, and quiescence. Western blot and transwell assays showed that *ZNF671* inhibited EMT, migration, and invasion of CNS cancers, lung cancer, melanoma, and breast carcinoma *in vitro*. These results suggested a crucial tumor suppressor role for *ZNF671* in the progression of these cancers, which was consistent with our previous studies ([@B26], [@B27]).

To further explore the heterogeneous functional state of *ZNF671* in cancers, we applied t-SNE to describe the distribution of cells. We found different cell clusters on a t-SNE map and proposed that these cell subgroups might lead to cancer functional heterogeneity. Functional analysis of the cancer cell subgroups validated that the heterogeneous cell populations had different roles in cancer progression and development, which provided us with a fine level of resolution for cancer treatment. However, there were still several limitations. First, this study was based on current scRNA datasets, and several scRNA datasets only contain data for hundreds of single cells, so more cells should be considered for analysis. Second, we found the *ZNF671* inhibits angiogenesis, apoptosis, EMT, hypoxia, invasion, and quiescence in CNS cancers, lung cancer, melanoma, and breast carcinoma. Moreover, we only identified that *ZNF671* suppresses cell EMT, migration, and invasion in *vitro*. The angiogenesis, apoptosis, hypoxia, and quiescence functional states need be identified further, and the suppressor role of *ZNF671 in vivo* needs to be explored further.

In conclusion, this study systematically evaluated the tumor suppressor role of *ZNF671* based on scRNA-seq datasets. Our findings revealed that *ZNF671* is a tumor suppressor in LUAD, BRCA, GBM, glioma, AST, ODG, and MEL. However, the mechanism of *ZNF671*\'s tumor suppressor role remains unknown, and further studies are needed to clarify this issue. Our results provide new insights into the role of *ZNF671* in multiple tumors and identifies *ZNF671* as a novel target for cancer treatment.
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